ArriVent BioPharma (AVBP) Research & Development (2023 - 2026)
ArriVent BioPharma (AVBP) posted Research & Development of $37.6 million for Q1 2026, up 16.91% sequentially from $32.2 million in Q4 2025, and down 38.62% YoY from $61.3 million in Q1 2025.
ArriVent BioPharma (AVBP) Research & Development (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Research & Development for 4 years, with the latest figure at $37.6 million in Q1 2026.
- Quarterly Research & Development fell 38.62% year-over-year to $37.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.7 million (up 5.16% YoY) and the FY2025 annual result came in at $153.4 million, up 94.11% from the prior year.
- Research & Development advanced to $37.6 million in Q1 2026 per AVBP's latest filing, from $32.2 million in the prior quarter.
- Over five years, Research & Development peaked at $61.3 million in Q1 2025 and troughed at $10.2 million in Q1 2023.
- A 4-year average of $25.8 million and a median of $20.4 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2025 and 2026: Research & Development surged 261.05% in 2025, then plunged 38.62% in 2026.
- Over 4 years, Research & Development stood at $20.0 million in 2023, then rose by 0.76% to $20.2 million in 2024, then jumped by 59.57% to $32.2 million in 2025, then rose by 16.91% to $37.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $37.6 million, $32.2 million, and $32.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | 42.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.34 Mn |
| Mar 31, 2026 | 37.62 Mn |
| Dec 31, 2025 | 32.18 Mn |
| Sep 30, 2025 | 32.17 Mn |
| Jun 30, 2025 | 27.72 Mn |
| Mar 31, 2025 | 61.29 Mn |
| Dec 31, 2024 | 20.16 Mn |
| Sep 30, 2024 | 20.09 Mn |
| Jun 30, 2024 | 21.78 Mn |
| Mar 31, 2024 | 16.98 Mn |
| Dec 31, 2023 | 20.01 Mn |
| Sep 30, 2023 | 14.28 Mn |
| Jun 30, 2023 | 20.36 Mn |
| Mar 31, 2023 | 10.24 Mn |